Lannett Announces Positive Results of Facilities Inspection

PHILADELPHIA, Sep 29, 2010 (BUSINESS WIRE) -- Lannett Company, Inc. /quotes/comstock/14*!lci/quotes/nls/lci (LCI 4.54, +0.16, +3.65%) today said that the U.S. Food and Drug Administration (FDA) recently completed inspections of the company's manufacturing facilities in Philadelphia and Cody, Wyoming. The inspections concluded with zero observations at the company's facilities in Philadelphia and a total of two minor 483 observations at Lannett's wholly owned subsidiary Cody Laboratories (Cody), a manufacturer/supplier of pain management pharmaceutical products.

"We are committed to maintaining a high level of quality and integrity in the products we manufacture," Arthur Bedrosian, president and chief executive officer of Lannett. "The positive results of these inspections underscore our companywide commitment to regulatory excellence."

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company's website at

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.